192 related articles for article (PubMed ID: 30016648)
1. Reversal of epigenetic aberrations associated with the acquisition of doxorubicin resistance restores drug sensitivity in breast cancer cells.
Ponnusamy L; Mahalingaiah PKS; Chang YW; Singh KP
Eur J Pharm Sci; 2018 Oct; 123():56-69. PubMed ID: 30016648
[TBL] [Abstract][Full Text] [Related]
2. Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest.
Vijayaraghavalu S; Dermawan JK; Cheriyath V; Labhasetwar V
Mol Pharm; 2013 Jan; 10(1):337-52. PubMed ID: 23215027
[TBL] [Abstract][Full Text] [Related]
3. Chronic Oxidative Stress Increases Resistance to Doxorubicin-Induced Cytotoxicity in Renal Carcinoma Cells Potentially Through Epigenetic Mechanism.
Ponnusamy L; Mahalingaiah PK; Singh KP
Mol Pharmacol; 2016 Jan; 89(1):27-41. PubMed ID: 26519223
[TBL] [Abstract][Full Text] [Related]
4. Epigenetics and miRNA as predictive markers and targets for lung cancer chemotherapy.
El-Awady RA; Hersi F; Al-Tunaiji H; Saleh EM; Abdel-Wahab AH; Al Homssi A; Suhail M; El-Serafi A; Al-Tel T
Cancer Biol Ther; 2015; 16(7):1056-70. PubMed ID: 25962089
[TBL] [Abstract][Full Text] [Related]
5. Long-term exposure to estrogen enhances chemotherapeutic efficacy potentially through epigenetic mechanism in human breast cancer cells.
Chang YW; Singh KP
PLoS One; 2017; 12(3):e0174227. PubMed ID: 28323900
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets.
Chekhun VF; Lukyanova NY; Kovalchuk O; Tryndyak VP; Pogribny IP
Mol Cancer Ther; 2007 Mar; 6(3):1089-98. PubMed ID: 17363502
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of ABCB4 contributes to acquired doxorubicin resistance in breast cancer cells in vitro.
Huang JF; Wen CJ; Zhao GZ; Dai Y; Li Y; Wu LX; Zhou HH
Cancer Chemother Pharmacol; 2018 Aug; 82(2):199-210. PubMed ID: 29777275
[TBL] [Abstract][Full Text] [Related]
8. Nanogel-mediated delivery of a cocktail of epigenetic drugs plus doxorubicin overcomes drug resistance in breast cancer cells.
Vijayaraghavalu S; Labhasetwar V
Drug Deliv Transl Res; 2018 Oct; 8(5):1289-1299. PubMed ID: 29947019
[TBL] [Abstract][Full Text] [Related]
9. DNA demethylation by 5-aza-2-deoxycytidine treatment abrogates 17 beta-estradiol-induced cell growth and restores expression of DNA repair genes in human breast cancer cells.
Singh KP; Treas J; Tyagi T; Gao W
Cancer Lett; 2012 Mar; 316(1):62-9. PubMed ID: 22082530
[TBL] [Abstract][Full Text] [Related]
10. Targeting the Epigenome as a Novel Therapeutic Approach for Breast Cancer.
Oh S; Ko JY; Oh C; Yoo KH
Adv Exp Med Biol; 2017; 1026():287-313. PubMed ID: 29282690
[TBL] [Abstract][Full Text] [Related]
11. Restoring microRNA-34a overcomes acquired drug resistance and disease progression in human breast cancer cell lines via suppressing the ABCC1 gene.
Yahya SMM; Nabih HK; Elsayed GH; Mohamed SIA; Elfiky AM; Salem SM
Breast Cancer Res Treat; 2024 Feb; 204(1):133-149. PubMed ID: 38057687
[TBL] [Abstract][Full Text] [Related]
12. Treatment schedule and estrogen receptor-status influence acquisition of doxorubicin resistance in breast cancer cells.
Ponnusamy L; Mahalingaiah PKS; Singh KP
Eur J Pharm Sci; 2017 Jun; 104():424-433. PubMed ID: 28455002
[TBL] [Abstract][Full Text] [Related]
13. [Effects of 5-Aza-2'-deoxycytidine and trichostatin A on DNA methylation and expression of hMLH1 in ovarian cancer cell line COC1/DDP].
Meng CF; Dai DQ; Guo KJ
Ai Zheng; 2008 Dec; 27(12):1251-5. PubMed ID: 19079988
[TBL] [Abstract][Full Text] [Related]
14. HLJ1 (DNAJB4) Gene Is a Novel Biomarker Candidate in Breast Cancer.
Acun T; Doberstein N; Habermann JK; Gemoll T; Thorns C; Oztas E; Ried T
OMICS; 2017 May; 21(5):257-265. PubMed ID: 28481734
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of histone H2A and H2B pathways is associated with anthracycline sensitivity in breast cancer.
Braunstein M; Liao L; Lyttle N; Lobo N; Taylor KJ; Krzyzanowski PM; Kalatskaya I; Yao CQ; Stein LD; Boutros PC; Twelves CJ; Marcellus R; Bartlett JM; Spears M
Breast Cancer Res; 2016 Feb; 18(1):16. PubMed ID: 26852132
[TBL] [Abstract][Full Text] [Related]
16. Suberoylanilide hydroxamic acid-induced specific epigenetic regulation controls Leptin-induced proliferation of breast cancer cell lines.
Feng X; Han H; Zou D; Zhou J; Zhou W
Oncotarget; 2017 Jan; 8(2):3364-3379. PubMed ID: 27926517
[TBL] [Abstract][Full Text] [Related]
17. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
Raha P; Thomas S; Thurn KT; Park J; Munster PN
Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic modulation of the biophysical properties of drug-resistant cell lipids to restore drug transport and endocytic functions.
Vijayaraghavalu S; Peetla C; Lu S; Labhasetwar V
Mol Pharm; 2012 Sep; 9(9):2730-42. PubMed ID: 22817326
[TBL] [Abstract][Full Text] [Related]
19. miRNA expression patterns in chemoresistant breast cancer tissues.
Lv J; Xia K; Xu P; Sun E; Ma J; Gao S; Zhou Q; Zhang M; Wang F; Chen F; Zhou P; Fu Z; Xie H
Biomed Pharmacother; 2014 Oct; 68(8):935-42. PubMed ID: 25451164
[TBL] [Abstract][Full Text] [Related]
20. 5-Aza-2-deoxycytidine and trichostatin A increase COUP-TFII expression in antiestrogen-resistant breast cancer cell lines.
Al-Rayyan N; Litchfield LM; Ivanova MM; Radde BN; Cheng A; Elbedewy A; Klinge CM
Cancer Lett; 2014 May; 347(1):139-50. PubMed ID: 24513177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]